Compare CLMB & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLMB | TBPH |
|---|---|---|
| Founded | 1982 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 506.0M | 993.7M |
| IPO Year | N/A | N/A |
| Metric | CLMB | TBPH |
|---|---|---|
| Price | $109.65 | $18.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $136.00 | $27.80 |
| AVG Volume (30 Days) | 50.9K | ★ 516.8K |
| Earning Date | 10-29-2025 | 11-10-2025 |
| Dividend Yield | ★ 0.63% | N/A |
| EPS Growth | ★ 26.05 | N/A |
| EPS | ★ 4.64 | 0.58 |
| Revenue | ★ $620,431,000.00 | $80,327,000.00 |
| Revenue This Year | $37.27 | $70.78 |
| Revenue Next Year | $4.75 | N/A |
| P/E Ratio | ★ $23.24 | $31.31 |
| Revenue Growth | ★ 51.09 | 27.12 |
| 52 Week Low | $88.90 | $7.90 |
| 52 Week High | $145.02 | $20.33 |
| Indicator | CLMB | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 45.97 | 54.58 |
| Support Level | $106.06 | $17.25 |
| Resistance Level | $111.93 | $20.32 |
| Average True Range (ATR) | 4.45 | 0.73 |
| MACD | 1.47 | -0.28 |
| Stochastic Oscillator | 76.07 | 30.62 |
Climb Global Solutions Inc is a cloud-based, value-added IT distribution and solutions company specializing in emerging technologies. It operates across the USA, Canada, and Europe through multiple business units, including Climb Channel Solutions, Sigma, Grey Matter, Interwork, and TechXtend. The company is organized into two reportable operating segments. The Distribution segment distributes technical software to corporate resellers, value-added resellers (VARs), consultants, and systems integrators under the name Climb Channel Solutions. The Solutions segment is a cloud solutions provider and value-added reseller of software, hardware, and services to customers under the name Grey Matter.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).